New ACI Report Highlights the Dangers of Overregulating E-Cigarette and Vaping Products

Washington D.C., January 14, 2022 — Today, the American Consumer Institute (ACI) released a report, co-authored by Steve Pociask and Liam Sigaud entitled “How Regulations Endanger the Public Health: A Review of the Evidence on E-Cigarette Risks and Benefits, and Policy Missteps.” With some lawmakers looking to impose restrictions, bans, and excessive taxes on these […]

ACI Letter to U.S. Senate: Proposed Antitrust Legislation Will Harm Consumers and Small Businesses

Dear Senators, As longtime advocates for policies that increase consumer choice, boost competition, and protect consumers, the American Consumer Institute Center for Citizen Research (ACI), a 501(c)(3) non-partisan research and educational institute, has analyzed and highlighted numerous times the negative effects the American Innovation and Choice Online Act (S. 2992) would have on consumer and […]

ACI Statement on the Markup of American Innovation and Choice Online Act (S. 2992) — “Have a hearing!”

Scheduling the bill for a markup without a committee hearing that could place concerns under scrutiny is extremely concerning given the numerous ramifications the bill could project.  Without evidence to support their claims, supporters of the bill might suggest that it would not negatively affect the services and products consumers currently enjoy, but unfortunately, the […]

Congress Should Investigate FTC’s Zombie Votes

A coalition letter made up of expert policy groups was sent to the U.S. Senate, House of Representatives, and Inspector General of the Federal Trade Commission (FTC) calling for an investigation of FTC’s practice of counting “zombie votes.” On October 1st and 8th of 2021, departed FTC Commissioner Rohit Chopra voted on official commission business […]

ACI Files Comments with the FCC on the New Affordable Connectivity Program

Yesterday, American Consumer Institute submitted comments to the Federal Communications Commission in a proceeding regarding proposed rules, procedures, and practices for the newly established Affordable Connectivity Program. In the filing, we recommend a smooth and efficient transition to the Affordable Connectivity Program, as the means to continue the Commission’s efforts to address the digital divide. […]

Coalition Opposes Congressional Attempt to Stifle Lower-Priced Generic Drug Competition

A coalition of policy think tanks sent a letter to Congress warning them that proposed legislation would have severe adverse consequences on consumers by significantly impeding the market entry of generic drug manufacturers. These generic drug companies offer much lower-priced drug for patients because they compete against name brand products — sometimes saving patients 90% […]

Departed FTC Commissioners Should Not Have a Commission Vote

From October 1, 2021 to October 8, 2021, the Federal Trade Commission (FTC) allowed the departed-Commissioner Rohit Chopra to vote via email as many as twenty times on Agency actions. The following coalition letter to Congress points to the lack of public transparency, calling for a Congressional investigation. That coalition letter is available online.

Coalition Letter Opposing FCC Nomination

A coalition of think tanks and public policy experts sent a letter to the U.S. Senate urging them to oppose the nomination of Gigi Sohn because of her radical partisan views. The letter says that the potential for Sohn to become chair of the FCC makes her nomination very concerning, because confirmation would jeopardize investment […]

Does CHEGG Deserve a Pass?

The following is a statement from Steve Pociask, president of the American Consumer Institute: “In a recent Heard on the Street column (“Chegg Deserves a Pass”), Jinjoo Lee cites a strong balance sheet and significant international growth prospects as sources of confidence for investors in the wake of the company’s brutal third quarter earnings results. […]

Coalition Tells Congress: Say “No” to Price Controls

Today, a large coalition of think tanks sent a letter to members of Congress opposing efforts to place artificial prices on prescription drugs. The letter explains that such price controls would lead to drug shortages, impede investment and innovation, and lead to worse outcomes for patients. The letter is available online.